These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11419669)

  • 1. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy.
    Craig WA
    Respir Med; 2001 Jun; 95 Suppl A():S12-9; discussion S26-7. PubMed ID: 11419669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How can we predict bacterial eradication?
    Jacobs MR
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and antimicrobial pharmacodynamics.
    Wise R
    Hosp Med; 2000 Jan; 61(1):24-30. PubMed ID: 10735149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg?
    Garau J
    Respir Med; 2001 Jun; 95 Suppl A():S5-11; discussion S26-7. PubMed ID: 11419672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
    Appelbaum PC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics to combat resistance.
    Woodnutt G
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():25-31. PubMed ID: 10997596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bacterial resistance and pharmacodynamics as the basis for prescribing antibiotics in respiratory infections].
    Aguado-García JM; Martín-Herrero JE; Lumbreras-Bermejo C
    Enferm Infecc Microbiol Clin; 2004 Apr; 22(4):230-7. PubMed ID: 15056440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.
    Jacobs MR
    Clin Microbiol Infect; 2001 Nov; 7(11):589-96. PubMed ID: 11737083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
    Calbo E; Garau J
    Respiration; 2005; 72(6):561-71. PubMed ID: 16354997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative study on bacterial eradication rate and clinical efficacy of CDTR, CFPN, and FRPM for treatment of children with otitis media and lower respiratory tract infection due to Streptococcus pneumoniae and Haemophilus influenzae].
    Sakata H
    Jpn J Antibiot; 2001 May; 54 Suppl B():96. PubMed ID: 12638154
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of pharmacokinetic/pharmacodynamic principles to predict clinical outcome in paediatric acute otitis media.
    Dagan R
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S127-30. PubMed ID: 17980558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Med; 2006 Jun; 119(6 Suppl 1):S37-44; discussion S62-70. PubMed ID: 16735150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory tract infection: epidemiology and surveillance.
    Jacobs MR
    J Chemother; 1997 May; 9 Suppl 3():10-7. PubMed ID: 9248976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections.
    Andes D
    Curr Opin Infect Dis; 2001 Apr; 14(2):165-72. PubMed ID: 11979128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles.
    Nicolau DP
    Infection; 2001 Dec; 29 Suppl 2():11-5. PubMed ID: 11785851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Resistance of infectious agents involved in low respiratory tract infections in France].
    Varon E; Houssaye S
    Med Mal Infect; 2006; 36(11-12):555-69. PubMed ID: 16962730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.
    Okamoto H; Miyazaki S; Tateda K; Ishii Y; Yamaguchi K
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3250-2. PubMed ID: 11600393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of coamoxiclav and other antibiotics against S pneumoniae and H influenae from paediatric cases of acute respiratory infections.
    Krishnan P; Rajendran P; Sambandan AP; Anitha C; Chavda RK; Khobragade KJ
    J Indian Med Assoc; 2011 Apr; 109(4):241-2, 244. PubMed ID: 22187795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.